DAAs, direct-acting antivirals; DIHS, drug-induced hypersensitivity syndrome; DRESS, drug rash with eosinophilia and systemic symptoms; HCV, hepatitis C virus; CHC, chronic hepatites C; Peg-IFN, pegylated interferon; RBV, ribavirin; RVR, rapid virological response; SJS, Stevens--Johnson syndrome; SVR, sustained virological response; TPV, telaprevir; TEN, toxic epidermal necrolysis
Introduction
Hepatitis C is a major pathogen causing liver cirrhosis and hepatocellular carcinoma worldwide. Until recently, standard therapies for chronic hepatitis C virus (HCV) genotype 1 infection were based on the combination of pegylated interferon (PEG-IFN) and ribavirin (RBV); these combination therapies yield a sustained virological response (SVR) rate of ~50% (1) . Several classes of novel direct-acting antivirals (DAAs) were recently developed and tested in clinical trials. Two first-generation HCV NS3/4A protease inhibitors, boceprevir (2, 3) , and telaprevir (4-6), have been approved for the treatment of genotype 1 HCV infection. The inclusion of these agents in HCV treatment regimens has led to large improvements in treatment success rates.
Telaprevir, the first DAA, is administered in combination with PEG-IFN and RBV for 24 weeks, resulting in SVR rates up to 70-80% (4, (6) (7) (8) . Although the telaprevir combination regimen is highly effective, the high frequency and severity of adverse events are outstanding issues limiting its use. Dermatological reactions are particularly prevalent, developing in 56-84.6% of patients treated with telaprevir, PEG-IFN, and RBV combination therapy (9, 10) . Moreover, the prevalence of severe dermatological reactions including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug-induced hypersensitivity syndrome (DIHS) are substantially higher in patients treated with telaprevir-based therapy than PEG-IFN and RBV combination therapy (8, 10) . McHutchison et al. reported that 7% of patients treated with telaprevir, PEG-IFN, and RBV combination therapy discontinue therapy because of rash or pruritus in contrast to only 1% of patients treated with PEG-IFN and RBV (8) . In some patients, serious skin reactions persist even after stopping all drugs (10) . However, the pathogenesis and clinical predictors of these adverse reactions are poorly understood.
Granulysin is a 15-kDa cationic cytolytic protein released by cytotoxic T lymphocytes and natural killer cells that induces apoptosis in target cells and has antimicrobial activities (11) . Serum levels of granulysin are elevated in primary virus infections including Epstein-Barr virus and parvovirus B19 (12) . It was recently reported that serum granulysin levels are significantly elevated in patients with several types of severe dermatological lesions including SJS/TEN, which is the characteristic serious adverse event in telaprevir-containing regimens(13) (14) .
Accordingly, the present study determined the risk factors for severe dermatological reactions in patients receiving telaprevir, PEG-IFN, and RBV combination therapy as well as the association between serum levels of granulysin and severe dermatological reactions. Written Informed consent according to the process approved by the hospital's ethics committee was obtained from each patient. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and was approved by the ethics committee of each participating hospital.
Methods

Patients and methods
In
Study design and treatment regimen
Telaprevir 500 or 750 mg was typically administered every 8 hours after meals for 12 weeks. PEG-IFN-a-2b (Peg-Intron, MSD, Tokyo, Japan) 1.5 IU/kg was administered subcutaneously once per week for 24 weeks. RBV (Rebetol, MSD) was administered for 24 weeks in two-divided dairy doses according to body weight: 600, 800, and 1,000 mg for patients with body weight <60, 60-80, and >80 kg, respectively.
The doses of PEG-IFN-a-2b, RBV, and telaprevir were reduced at the attending physician's discretion on the basis of hemoglobin levels, decreased white blood cell or platelet count, or adverse events.
During treatment, patients were assessed as outpatient at weeks 1, 2, 4, 6, and 8 and then every 4 weeks thereafter for the duration of treatment. Physical examinations and blood tests were performed at all time points.
Outcomes
The primary endpoint was SVR, which was defined as serum HCV RNA undetectable at 24 weeks after the end of treatment. The secondary endpoints were end-of-treatment virological responses (HCV RNA undetectable in serum) and rapid virological response (RVR), which was defined as serum HCV RNA undetectable at 4 weeks after the start of treatment. Dermatological reactions were classified according to severity in the same manner as in phase III trials in Japan (10) .
Serum granulysin measurement
To evaluate serum granulysin levels in chronic hepatitis C, we first measured serum granulysin levels in 5 healthy volunteers and compared them with those of 20 chronic hepatitis C patients before treatment. Serum granulysin levels were measured at the onset of dermatological reactions (within 3 days of onset); if the symptoms worsened, the time when worsening occurred was adopted. Meanwhile, in patients with no dermatological reactions, the highest serum granulysin level during treatment was adopted.
Serum granulysin levels were measured by a sandwich-enzyme-linked immunosorbent assay as described previously (12, 14, 15) . Briefly, plates coated with 5 mg/mL mouse antibody against human granulysin, RB1 antibody, were washed with phosphate-buffered saline containing 0.1% Tween-20. Next, they were blocked with 10% fetal bovine serum in washing buffer at room temperature for 2 hours. The samples and standards (Recombinant Granulysin, R&D Systems, Minneapolis, MN, USA) were incubated for 2 hours at room temperature. Next, they were reacted with 0.1 mg/mL biotinylated another mouse antibody against human granulysin, RC8 antibody. The plates were subsequently treated with horseradish peroxidase-conjugated streptavidin (Roche Diagnostics, Basel, Switzerland). The plates were then incubated with tetramethylbenzidine substrate (Sigma, St. Louis, MO, USA), and 1 M sulfuric acid was then added. The optical density was measured at 450 nm using a microplate reader
Diagnosis of dermatological reactions
Dermatological reactions were investigated throughout the 24-week administration period in the telaprevir-based combination therapy. Dermatological reactions were classified according to severity as follows. Grade 1 was defined as involvement of <50% of the body surface and no evidence of systemic symptoms.
Grade 2 was defined as involvement of <50% of the body surface but with multiple or diffuse lesions or rashes with characteristic mild systemic symptoms or mucous membrane involvement with no ulceration/erosion. Grade 3 was defined as a generalized rash involving >50% of the body surface or a rash with any new significant systemic symptoms and considered to be related to the onset and/or progression of the rash. Life-threatening reactions included SJS, TEN, drug rash with eosinophilia and systemic symptoms (DRESS)/DIHS, erythema multiforme, and other life-threatening symptoms or patients presenting with features of serious disease.
When adverse skin reactions were detected, the attending physician classified the degree of severity and referred the patients to a dermatologist as needed. In principal, when grade 3 dermatological reactions occurred, the attending physician referred the patient to a dermatologist and discontinued telaprevir. When severe dermatological reactions including SJS/TEN and DRESS/DIHS were suspected, all drugs were discontinued immediately. SJS/TEN and DIHS were diagnosed by skin biopsy and according to disease criteria, respectively.
Statistical analysis
Categorical and continuous variables were analyzed by the χ 2 test and the unpaired Mann-Whitney U-test, respectively. All P-values were two-tailed, and the level of significance was set at P < 0.05. Multivariate logistic regression analysis with stepwise forward selection included variables showing P < 0.05 in univariate analyses.
The association between dermatological reactions and serum granulysin levels were evaluated by one-way analysis of variance followed by the Tukey honestly significant different test. All statistical analyses were performed using SPSS version 21.0 (IBM Japan, Tokyo, Japan)
Results
Patients.
We included 123 CHC patients who received telaprevir based triple therapy. Of these, 89 patients who had proper information of dermatological adverse events were included. The base line characteristic of patients is shown in Table1. Among 89 patients, 64% (57/89) developed dermatological reactions, including 9 with grade 3 reactions ( Table 2 ). The characteristics of dermatological reactions by grade are shown in Table 2 . Non-grade 3 dermatological reactions tended to occur early during treatment compared to grade 3 dermatological reactions.
Association between dermatological reactions and treatment outcomes
First, we determined whether dermatological reactions were associated with final treatment outcomes. Univariate analyses identified baseline white blood cell and platelet counts, RVR, and non-grade 3 dermatological reactions significantly associated with SVR ( Table 3) . Among 9 patients with grade3 dermatological reactions, 3 patients discontinued of all treatment and 6 patients discontinued of telaprevir administration, SVR was achieved 0/3 (0%) and 2/6 (33%) respectively.
Multivariate analysis showed that RVR and non-grade 3 dermatological reactions were significantly associated with SVR ( Table 3) .
Analysis of risk factors for telaprevir-induced dermatological reactions
Next, we analyzed the association between severe (i.e., grade 3) dermatological reactions and clinical parameters ( Table 4 ). Univariate analysis showed that only sex was significantly associated with the grade 3 dermatological reactions (P = 0.03).
Serum granulysin levels in healthy subjects and chronic hepatitis C patients
As shown in Figure 1 , serum granulysin levels did not differ significantly between healthy volunteers and chronic hepatitis C patients. Next, we evaluated the association between the severity of dermatological reactions and serum peak granulysin levels in 20 patients including 5, 4, 5, 6 with grade 1, grade 2, grade 3, and no dermatological events, respectively. One-way analysis of variance showed that serum granulysin level was significantly associated with the severity of dermatological reactions (P = 0.036); in addition, the Tukey honestly significant difference test revealed that the serum granulysin levels of patients with grade 3 dermatological reactions were significantly higher than those of patients with grade 1 or no dermatological reactions (both P < 0.05, Figure 2 ).
Time-dependent changes in serum granulysin levels
We investigated the time-dependent changes in serum granulysin levels in 5 and 15 patients with grade 3 and non-grade 3 dermatological reactions, respectively (Figure 3a, b) . Serum granulysin levels of patients with non-grade 3 dermatological reactions never exceeded more than 10ng/ml. Of the 5 patients with grade 3 reactions, 3
had severe systemic manifestations that necessitated hospital admission: 1 each had SJS, DIHS, and systemic lymphoid swelling and high fever (>39°C). All patients with grade 3 dermatological reactions with systemic manifestations had peak serum granulysin levels exceeding 10ng/mL; importantly, the serum granulysin levels of 2 patients already exceeding 8 ng/mL at the onset of the reactions and worsened within six days
Discussion
The present study demonstrates a significant association between telaprevir-induced dermatological reactions and elevated serum granulysin levels for the first time. Moreover, serum granulysin levels were significantly associated with the severity of dermatological reactions. Thus, the results indicate that serum granulysin level seems to be a useful predictor of telaprevir-induced dermatological reactions.
Because the emergence of grade 3 dermatological reactions was significantly associated with non-SVR (Table 3) , probably associated with high rate of treatment discontinuation, it is important to predict dermatological events in the early stage to achieve good treatment outcomes.
Recent genome-wide association studies have identified that genetic polymorphisms around the IL28B gene locus significantly associated with the outcome of PEG-IFN and RBV combination therapy in HCV patients. Thus, PEG-IFN and RBV combination therapy is ineffective in a subset of HCV-infected patients who have IL28B TG or GG genotypes, limiting the use of this therapy (16) . Therefore, novel drugs with different anti-viral mechanisms were required. Accordingly, DAAs were developed; they are mainly classified as NS3/4A protease inhibitors, or NS5B or NS5A inhibitors (17) . The NS3/4A serine protease inhibitor telaprevir, in combination with PEG-IFN and RBV, has demonstrated the most promising results (6) (7) (8) . However, adverse events, especially severe dermatological reactions, develop more frequently in patients treated with telaprevir than those treated with only PEG-IFN and RBV.
Little is known about the mechanisms of telaprevir-induced dermatological reactions. Reactions develop in patients treated with PEG-IFN and RBV combination therapy (18, 19) as well as telaprevir monotherapy (20, 21) . It should be noted that the dermatological reactions in telaprevir monotherapy or PEG-IFN and RBV therapy alone are generally mild (7, 8, 20) . However, dermatological reactions in telaprevir and PEG-IFN/RBV combination therapy may be severe, indicating a synergistic effect.
Severe dermatological events including SJS/TEN and DIHS have been reported in telaprevir-based triple therapy; these are life threatening, and fatal cases have been reported.
The onset of grade 3 dermatological reactions tended to be later than non-grade 3 reactions, the same as in the study of Torii et al. (10) . Taken together with the finding that male sex is a clinical risk factor, the results indicate that late-onset dermatological reactions in male patients treated with telaprevir-based triple therapy require more attention.
Roujeau et al. analyzed the risk factors for telaprevir-induced eczematous dermatitis and report that the incidence of telaprevir-related dermatitis was significantly higher age >45 years, body mass index <30 (kg／m 2 ), Caucasian ethnicity, and treatment-naïve status (9) . While they analyzed the risk factors for telaprevir-induced eczematous dermatitis, the present study focused on the risk factors for severe telaprevir-induced dermatological reactions, because such reactions can affect treatment outcome ( Table 2 ) and can be fatal. As mentioned above, male sex was significantly associated with grade 3 dermatological reactions. Sex is reported to be associated with the prevalence of some kinds of severe drug-induced dermatological events although the underlying mechanism remains unknown (22). Fujita et al. report that serum granulysin levels are significantly elevated in SJS/TEN patients and thus might be good predictive factor (14) . Therefore, we hypothesized that in telaprevir-based triple therapy for chronic hepatitis C patients, serum granulysin levels are associated with the severity of dermatological reactions and might thus be a predictive biomarker. However, Ogawa et al. report that serum granulysin levels also increase as a result of primary virus infections such as Epstein-Barr virus or parvovirus B19 (12) . Thus, it remains unclear whether and how chronic viral infections, especially HCV, affect serum granulysin levels. In the present study, we compared serum granulysin levels between healthy volunteers and chronic hepatitis C patients; the results show that chronic HCV infection was not associated with serum granulysin levels (Figure 1) .
Chung et al. have reported that granulysin is the most highly expressed
cytotoxic molecule in blisters of SJS/TEN and that massive keratinocyte death was induced by granulysin (11) . Fujita et al. reported that serum granulysin levels increased in early stage of SJS/TEN caused by drug including carbamazepine, imatinib and phenytoin (14) . Taken together with our results, we speculate that granulysin may be involved in the pathogenesis of early stage of telaprevir-mediated dermatological adverse reactions possibly through induction of keratinocyte death.
Of 5 patients with grade 3 reactions, 2 patients without severe systemic manifestations did not elevate serum granulysin more than 10ng/ml or did not elevate before symptom worsen. On the contrary, 3 patients with severe systemic manifestations had peak serum granulysin levels exceeding 10ng/mL and the serum granulysin levels of 2 patients already exceeding 8ng/ml at onset and within 6 days, symptoms worsen. Therefore serum granulysin tests might predict grade3 dermatological adverse reaction with systemic manifestations. Furthermore if serum granulysin levels elevate more than 8ng/mL, more attention should be paid.
In Western countries, the prevalence of dermatological reactions in patients treated with telaprevir-based and PEG-IFN/RBV therapy are reported to be approximately 55% and 33%, respectively(9, 23); meanwhile, in Japanese patients, the respective rates are 74.9% and 58.7%. Moreover, approximately 4% and 9.0% of patients in Western and Japanese patients develop grade 3 reactions, respectively (10); this is almost the same as that in the present study (10%). The difference may be due to genetic or ethnic variation. Therefore, genome-wide association studies may have identified a gene locus associated with telaprevir-induced severe dermatological reactions.
A limitation of this study is that the number of patients with grade3 dermatological reactions is relatively small. However, the serum granulyasin levels of patients with grade3 dermatological reactions were significantly higher than those of other patients. And in two of the three patients with severe dermatological reactions, the serum granulysin level elevated before symptoms worsen, these would be novel findings. Further study would be required.
Triple therapy with the second-generation protease inhibitor simeprevir is reported to result in a similar prevalence of adverse reactions as PEG-IFN and RBV combination therapy (24, 25). However, simeprevir is not approved worldwide.
Although simeprevir-based triple therapy is effective, but only 36-53% of prior non-responders achieve SVR (24). Shimada et al. recently reported that by extending PEG-IFN and RBV therapy from 24 to 48 weeks, telaprevir-based triple therapy improves the SVR to up to 68% in prior null responders (26). Thus, telaprevir is a therapeutic option for prior null responders.
In conclusion, the present study suggests that male sex is a significant risk factor for severe telaprevir-induced dermatological reactions. In addition, serum granulysin levels are significantly associated with the severity of dermatological reactions and thus might be a good predictor of severe dermatological reactions with systemic manifestations in patients treated with telaprevir-based triple therapy. 
Figure 2. Association between dermatological adverse reaction severity and serum granulysin level
Serum granulysin levels were measured at the onset of dermatological reactions (i.e., within 3 days of onset); if the symptoms worsened, the time of worsening was adopted.
In patients with no dermatological events, the highest serum granulysin level during treatment was adopted. P < 0.05, one-way analysis of variance. 
